Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
NEW YORK, NY, May 02, 2018 -- IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that it will be presenting at the 3rd annual Disruptive Growth & Healthcare Conference on Tuesday, May 8th at 12:50pm EDT. Tom LaVoy, CEO of IsoRay, will be presenting as well as meeting with investors.
Tom LaVoy, IsoRay’s CEO, will also be a participant on a panel discussion at 1:45pm EDT entitled “Disruptive Injectables & Oncology”.
The 2018 Disruptive Growth & Healthcare Conference will offer the exclusive opportunity to discover life science companies focusing on solutions to unmet medical needs and growth companies with disruptive technologies and business models.
For those interested in attending, please visit www.DisruptNYC.com for more information.
About IsoRay, Inc.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Join us on Facebook/IsoRay. Follow us on Twitter@IsoRay.
About RHK Capital:
Advisory Group Equity Services, Ltd. (dba RHK Capital) was founded in 1984. RHK Capital is a boutique investment banking firm specializing in small to medium-sized transactions. RHK is led by a management team with extensive financial industry experience and a desire to provide companies and individuals with the tools and expertise to accomplish their financial goals. In addition to investment banking, RHK has grown to include businesses in general securities, emerging market securities, distressed and high yield debt securities, investment management, mortgages, and business lending. As a division of Advisory Group Equity Services (AGES), all securities are offered through Advisory Group Equity Services Ltd., a registered broker-dealer, member of the Financial Industry Regulatory Authority and the Securities Investor Protection Corporation.
Contacts: IsoRay Inc. [email protected] (509) 375-1202 Investors: Stephanie Prince, Managing Director PCG Advisory Group [email protected] (646) 762-4518
